
RenovoRx (RNXT) Stock Forecast & Price Target
RenovoRx (RNXT) Analyst Ratings
Bulls say
RenovoRx is on a path to success with their unique focus on precision oncology therapies, and their recent announcement of the positive results from their second pre-planned interim analysis only increases the potential for a positive outcome in the future. With 36 active commercial cancer centers by the end of 2026, revenue is expected to increase significantly and the ~billion dollars market potential presents high rewards for the risks. The company's new CFO and pro forma cash of $13M also add to their strong potential for success as they continue their clinical and commercial development efforts.
Bears say
RenovoRx is a clinical-stage biopharmaceutical company with a negative outlook due to their high cash burn rate, limited commercialization of their lead drug candidate RenovoGem, and a lack of significant revenue growth in the near future. With a historical focus on research and development rather than revenue generation, RenovoRx may struggle to meet financial expectations and may face difficulties in securing additional funding in the future.
This aggregate rating is based on analysts' research of RenovoRx and is not a guaranteed prediction by Public.com or investment advice.
RenovoRx (RNXT) Analyst Forecast & Price Prediction
Start investing in RenovoRx (RNXT)
Order type
Buy in
Order amount
Est. shares
0 shares